Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.

Andorrà M, Alba-Arbalat S, Camos-Carreras A, Gabilondo I, Fraga-Pumar E, Torres-Torres R, Pulido-Valdeolivas I, Tercero-Uribe AI, Guerrero-Zamora AM, Ortiz-Perez S, Zubizarreta I, Sola-Valls N, Llufriu S, Sepulveda M, Martinez-Hernandez E, Armangue T, Blanco Y, Villoslada P, Sanchez-Dalmau B, Saiz A, Martinez-Lapiscina EH.

JAMA Neurol. 2019 Sep 30. doi: 10.1001/jamaneurol.2019.3283. [Epub ahead of print]

PMID:
31566686
2.

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study.

Balk LJ, Coric D, Knier B, Zimmermann HG, Behbehani R, Alroughani R, Martinez-Lapiscina EH, Brandt AU, Sánchez-Dalmau B, Vidal-Jordana A, Albrecht P, Koska V, Havla J, Pisa M, Nolan RC, Leocani L, Paul F, Aktas O, Montalban X, Balcer LJ, Villoslada P, Outteryck O, Korn T, Petzold A; IMSVISUAL consortium.

Mult Scler J Exp Transl Clin. 2019 Sep 5;5(3):2055217319871582. doi: 10.1177/2055217319871582. eCollection 2019 Jul-Sep.

3.

Cockayne syndrome in adults: complete retinal dysfunction exploration of two case reports.

Figueras-Roca M, Budi V, Morató M, Camós-Carreras A, Muñoz JE, Sánchez-Dalmau B.

Doc Ophthalmol. 2019 Jun;138(3):241-246. doi: 10.1007/s10633-019-09681-y. Epub 2019 Feb 28.

PMID:
30820731
4.

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.

Saint-Jean A, Reguart N, Eixarch A, Adán A, Castellà C, Sánchez-Dalmau B, Sainz-de-la-Maza M.

J Fr Ophtalmol. 2018 Dec;41(10):955-962. doi: 10.1016/j.jfo.2018.07.005. Epub 2018 Nov 23.

PMID:
30473235
5.

Predictors of vision impairment in Multiple Sclerosis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Blanco Y, Sola-Valls N, Sepulveda M, Guerrero A, Alba S, Andorra M, Camos A, Sanchez-Vela L, Alfonso V, Saiz A, Villoslada P.

PLoS One. 2018 Apr 17;13(4):e0195856. doi: 10.1371/journal.pone.0195856. eCollection 2018.

6.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, Alba-Arbalat S, Guerrero-Zamora A, Calbet D, Villoslada P.

Mult Scler. 2018 Aug;24(9):1196-1204. doi: 10.1177/1352458517718628. Epub 2017 Jul 3.

PMID:
28669275
7.

Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.

Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S, Villoslada P, Sanchez-Dalmau B, Saiz A.

Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. doi: 10.1177/1756285616655264. Epub 2016 Aug 15. No abstract available.

8.

Phenytoin for neuroprotection.

Martinez-Lapiscina EH, Andorra M, Sanchez-Dalmau B, Villoslada P.

Lancet Neurol. 2016 Aug;15(9):901-902. doi: 10.1016/S1474-4422(16)30093-X. No abstract available.

PMID:
27478946
9.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
10.

Visual field impairment captures disease burden in multiple sclerosis.

Ortiz-Perez S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, Calbet D, Lampert EJ, Alba-Arbalat S, Guerrero-Zamora AM, Zubizarreta I, Sola-Valls N, Llufriu S, Sepúlveda M, Saiz A, Villoslada P, Martinez-Lapiscina EH.

J Neurol. 2016 Apr;263(4):695-702. doi: 10.1007/s00415-016-8034-2. Epub 2016 Feb 9.

PMID:
26860093
11.

Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Sepúlveda M, Sola N, Saiz A, Sánchez-Dalmau B, Villoslada P, Martínez-Lapiscina EH.

J Neurol. 2015 Nov;262(11):2491-7. doi: 10.1007/s00415-015-7876-3. Epub 2015 Aug 11.

PMID:
26259563
12.

Dynamics of retinal injury after acute optic neuritis.

Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorra M, Llufriu S, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2015 Mar;77(3):517-28. doi: 10.1002/ana.24351. Epub 2015 Feb 14.

PMID:
25559267
13.

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.

Martínez-Lapiscina EH, Fraga-Pumar E, Gabilondo I, Martínez-Heras E, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Tercero A, Andorra M, Roca MF, Lampert E, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

BMC Res Notes. 2014 Dec 15;7:910. doi: 10.1186/1756-0500-7-910.

14.

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A.

PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014.

15.

The visual pathway as a model to understand brain damage in multiple sclerosis.

Martínez-Lapiscina EH, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe AI, Torres-Torres R, Villoslada P.

Mult Scler. 2014 Nov;20(13):1678-85. doi: 10.1177/1352458514542862. Epub 2014 Jul 10. Review.

PMID:
25013155
16.

Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.

Martínez-Lapiscina EH, Fraga-Pumar E, Pastor X, Gómez M, Conesa A, Lozano-Rubí R, Sánchez-Dalmau B, Alonso A, Villoslada P.

J Neurol. 2014 Apr;261(4):759-67. doi: 10.1007/s00415-014-7266-2. Epub 2014 Feb 16.

PMID:
24532201
17.

Colour vision impairment is associated with disease severity in multiple sclerosis.

Martínez-Lapiscina EH, Ortiz-Pérez S, Fraga-Pumar E, Martínez-Heras E, Gabilondo I, Llufriu S, Bullich S, Figueras M, Saiz A, Sánchez-Dalmau B, Villoslada P.

Mult Scler. 2014 Aug;20(9):1207-16. doi: 10.1177/1352458513517591. Epub 2014 Jan 7.

PMID:
24399824
18.

Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, Bullich S, Sepulveda M, Falcon C, Berenguer J, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2014 Jan;75(1):98-107. doi: 10.1002/ana.24030. Epub 2014 Jan 2.

PMID:
24114885
19.

Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis.

Marro M, Taubes A, Abernathy A, Balint S, Moreno B, Sanchez-Dalmau B, Martínez-Lapiscina EH, Amat-Roldan I, Petrov D, Villoslada P.

J Biophotonics. 2014 Sep;7(9):724-34. doi: 10.1002/jbio.201300101. Epub 2013 Sep 6.

PMID:
24019106
20.

Retinal periphlebitis is associated with multiple sclerosis severity.

Ortiz-Pérez S, Martínez-Lapiscina EH, Gabilondo I, Fraga-Pumar E, Martínez-Heras E, Saiz A, Sanchez-Dalmau B, Villoslada P.

Neurology. 2013 Sep 3;81(10):877-81. doi: 10.1212/WNL.0b013e3182a3525e. Epub 2013 Jul 31.

Supplemental Content

Loading ...
Support Center